share_log

Transcode Therapeutics | 8-K: Current report

Transcode Therapeutics | 8-K: Current report

Transcode Therapeutics | 8-K：重大事件
美股SEC公告 ·  08/28 06:09
Moomoo AI 已提取核心信息
TransCode Therapeutics, Inc., a biotech company listed on the Nasdaq Capital Market, is facing potential delisting due to non-compliance with Nasdaq's listing requirements. The company received two deficiency letters from Nasdaq. The first, received on August 13, 2024, indicated that TransCode's common stock had not met the minimum bid price of $1.00 per share for 30 consecutive business days. The second letter, received on August 15, 2024, notified the company of its failure to meet the minimum stockholders' equity requirement of $2.5 million, with its equity standing at $1,322,274 as of June 30, 2024. Despite raising approximately $2.4 million in a July 2024 equity offering, there is no guarantee that Nasdaq will consider the company's stockholders' equity on a pro forma basis. TransCode does not meet alternative quantitative standards for continued listing either. The company has appealed the delisting decision and a hearing with the Nasdaq Hearings Panel is scheduled for October 1, 2024. The delisting action has been stayed pending the Panel's final decision, but there is no assurance that the company will regain compliance or avoid delisting.
TransCode Therapeutics, Inc., a biotech company listed on the Nasdaq Capital Market, is facing potential delisting due to non-compliance with Nasdaq's listing requirements. The company received two deficiency letters from Nasdaq. The first, received on August 13, 2024, indicated that TransCode's common stock had not met the minimum bid price of $1.00 per share for 30 consecutive business days. The second letter, received on August 15, 2024, notified the company of its failure to meet the minimum stockholders' equity requirement of $2.5 million, with its equity standing at $1,322,274 as of June 30, 2024. Despite raising approximately $2.4 million in a July 2024 equity offering, there is no guarantee that Nasdaq will consider the company's stockholders' equity on a pro forma basis. TransCode does not meet alternative quantitative standards for continued listing either. The company has appealed the delisting decision and a hearing with the Nasdaq Hearings Panel is scheduled for October 1, 2024. The delisting action has been stayed pending the Panel's final decision, but there is no assurance that the company will regain compliance or avoid delisting.
TransCode Therapeutics，一家在纳斯达克资本市场上市的生物技术公司，由于未能符合纳斯达克的上市要求，面临潜在摘牌风险。该公司收到了两封来自纳斯达克的违规通知。第一封信于2024年8月13日收到，指出TransCode的普通股在连续30个营业日中未达到每股1.00美元的最低买盘价。第二封信于2024年8月15日收到，通知该公司未能满足股东权益的最低要求250万美元，截至2024年6月30日，其股权为1,322,274美元。尽管该公司在2024年7月举行的股权发行中募集了大约240万美元，但纳斯达克并不保证会按照一项名义基础上计算该公司的股东权益。TransCode也未达到其他持续上市的定量标准。该公司已对摘牌决定提出上诉，并于2024年10月1日与纳斯达克听证委员会进行了听证。摘牌行动已暂停，等待委员会最终决定，但无法保证该公司能够恢复合规或避免摘牌。
TransCode Therapeutics，一家在纳斯达克资本市场上市的生物技术公司，由于未能符合纳斯达克的上市要求，面临潜在摘牌风险。该公司收到了两封来自纳斯达克的违规通知。第一封信于2024年8月13日收到，指出TransCode的普通股在连续30个营业日中未达到每股1.00美元的最低买盘价。第二封信于2024年8月15日收到，通知该公司未能满足股东权益的最低要求250万美元，截至2024年6月30日，其股权为1,322,274美元。尽管该公司在2024年7月举行的股权发行中募集了大约240万美元，但纳斯达克并不保证会按照一项名义基础上计算该公司的股东权益。TransCode也未达到其他持续上市的定量标准。该公司已对摘牌决定提出上诉，并于2024年10月1日与纳斯达克听证委员会进行了听证。摘牌行动已暂停，等待委员会最终决定，但无法保证该公司能够恢复合规或避免摘牌。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息